Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study

Nivolumab and cabozantinib are approved agents in mRCC patients after sunitinib/pazopanib (TKI) failure. However, the optimal sequence, cabozantinib then nivolumab (CN) or nivolumab then cabozantinib (NC), is still unknown. The CABIR study aimed to identify the optimal sequence between CN and NC aft...

Descripción completa

Detalles Bibliográficos
Autores principales: Vano, Yann‐Alexandre, Phan, Letuan, Gravis, Gwenaelle, Korakis, Iphigénie, Schlürmann, Friederike, Maillet, Denis, Bennamoun, Mostefa, Houede, Nadine, Topart, Delphine, Borchiellini, Delphine, Barthelemy, Philippe, Ratta, Raffaele, Ryckewaert, Thomas, Hasbini, Ali, Hans, Sophie, Emambux, Sheik, Cournier, Sandra, Braychenko, Elena, Elaidi, Réza‐Thierry, Oudard, Stéphane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541795/
https://www.ncbi.nlm.nih.gov/pubmed/35603906
http://dx.doi.org/10.1002/ijc.34126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541795/
https://www.ncbi.nlm.nih.gov/pubmed/35603906
http://dx.doi.org/10.1002/ijc.34126

Ejemplares similares